DSIP (Delta Sleep Inducing Peptide) [Nasal Spray]

Description

For laboratory research use only 

What is DSIP (Delta Sleep Inducing Peptide)?

Delta Sleep Inducing Peptide (DSIP) is a naturally occurring nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). It was first isolated from the cerebral venous blood of rabbits during electrically induced sleep states in 1977 and has since been the subject of extensive neuroendocrine and neurobiological preclinical investigation. DSIP is distributed endogenously in both free and bound forms across multiple CNS regions, including the hypothalamus, limbic system, and pituitary, as well as in peripheral organs and biological fluids.

Research interest in DSIP centers on its proposed role in neuroendocrine regulatory systems, circadian rhythm modulation, and stress response signaling in preclinical model systems. The peptide has been investigated for its interactions with sleep-related EEG parameters, pituitary hormone release dynamics, and stress-limiting mechanisms in rodent and in vitro preparations.

DSIP is not approved by the Food and Drug Administration (FDA) for any human therapeutic application. It is not a dietary supplement or consumer product. This product is intended exclusively for laboratory and research purposes.

Chemical Properties

Property	Detail
Product Type	Synthetic Nonapeptide / Neuropeptide
Product Name	DSIP (Delta Sleep Inducing Peptide) Nasal Spray
Application	Scientific / Research Use Only
CAS Number	62568-57-4
Molar Mass	848.81 g/mol
Chemical Formula	C₃₅H₄₈N₁₀O₁₅
IUPAC Name	H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH
Synonyms	DSIP; Emideltide; Delta-Sleep Inducing Peptide; WAGGDASGE; δ-Sleep Inducing Peptide
Physical Form	Aqueous nasal spray solution (lyophilized peptide reconstituted in sterile buffered solution)
Solubility	Soluble in water and aqueous buffers
Storage (Lyophilized)	−20°C, desiccated, protected from light
Storage (Reconstituted / Nasal Spray)	2–8°C; use within 28 days; protect from light; do not freeze reconstituted solution
PubChem CID	68816
Purity	≥98% (HPLC verified, independent third-party laboratory analysis; COA available per batch)
WADA Status	DSIP is not listed on the 2026 WADA Prohibited List as a specifically named prohibited substance. Researchers operating under WADA-governed contexts should independently verify current prohibited list status with their applicable governing body before use.

How Does DSIP Work?

Neuroendocrine Regulatory Activity

Mechanistically, DSIP has been investigated for its interactions with neuroendocrine regulatory axes in preclinical preparations. In rodent and in vitro systems, DSIP has been observed to modulate pituitary hormone release dynamics, including stimulation of growth hormone-releasing hormone (somatoliberin) secretion and inhibition of somatostatin release – interactions proposed to influence somatotropin dynamics in preclinical models , stimulation of growth hormone-releasing hormone (somatoliberin) and somatotropin secretion, and inhibition of somatostatin release. 

These interactions have been investigated in the context of hypothalamic-pituitary axis regulation, though the specific receptor or binding protein mediating DSIP’s neuroendocrine effects has not been definitively characterized in peer-reviewed literature. No dedicated DSIP receptor has been identified as of this publication date.

Corticotropin Axis Modulation

In preclinical preparations, DSIP has been associated with decreases in basal corticotropin (ACTH) levels and observed to attenuate corticotropin release in some experimental models. These findings position DSIP as a candidate modulator of hypothalamic-pituitary-adrenal (HPA) axis signaling in preclinical research contexts, though the molecular mechanism of this activity remains incompletely characterized and findings have not been consistent across all model systems examined.

EEG and Sleep Architecture Investigations

DSIP was originally characterized through its ability, following intraventricular infusion in rabbit preparations, to induce delta-wave (slow-wave) and spindle EEG activity and to reduce motor activity. These electrophysiological observations defined the compound’s classification and have driven research interest in its role in sleep regulatory signaling. The peptide’s ability to cross the blood-brain barrier has been investigated in preclinical animal models, with evidence from rodent studies suggesting passive CNS penetration. No specific neuroreceptor mediating these electrophysiological effects has been identified.

Stress-Limiting Mechanisms

In preclinical model systems, DSIP has been proposed to act as a stress-limiting neuropeptide. Investigations in rodent stress models have examined DSIP’s potential role in modulating stress-induced physiological responses, including interactions with corticotropin release systems and autonomic nervous system parameters. The precise molecular mechanism underlying stress-limiting activity remains unresolved.

Key Research Findings

These findings are derived exclusively from preclinical in vitro and in vivo animal studies. Data remains limited. Findings are not consistent across all models. This section does not constitute clinical evidence.

• EEG delta-wave induction: Intraventricular DSIP infusion in rabbit preparations originally reported to induce spindle and delta EEG activity and reduce motor activity in recipient animals. [Schoenenberger & Monnier, 1977; foundational characterization study]
• LH release stimulation: Preclinical models have observed DSIP-associated stimulation of luteinizing hormone (LH) release in pituitary preparations, positioning the peptide as a candidate modulator of hypothalamic-pituitary axis signaling.
• Somatostatin inhibition: In vitro and in vivo rodent preparations have identified DSIP-associated inhibition of somatostatin secretion alongside stimulation of growth hormone-releasing factor release.
• HPA axis modulation: Preclinical preparations have observed DSIP-associated decreases in basal corticotropin levels and attenuation of corticotropin release in some model systems; findings are not consistent across all experimental conditions. [Graf & Kastin, 1984 review; PMID: 6323232]
• BBB penetration: Preclinical rodent studies have provided evidence suggesting DSIP can passively penetrate the blood-brain barrier, a pharmacokinetically relevant property for CNS peptide research.

What Are the Potential Research Applications of DSIP?

DSIP Nasal Spray is investigated in preclinical research contexts encompassing the following areas:

• Neuroendocrine axis pharmacology: In vitro and in vivo model systems examining DSIP’s interactions with hypothalamic-pituitary hormone release dynamics, including LH, GH-releasing factor, somatostatin, and corticotropin modulation.
• Circadian rhythm and sleep signaling research: Rodent and ex vivo preparations investigating the electrophysiological and neurochemical correlates of DSIP activity in sleep-regulatory CNS networks.
• HPA axis stress response research: Preclinical model systems examining peptide-mediated modulation of corticotropin release and stress-related neuroendocrine parameters.
• Neuropeptide blood-brain barrier transport: Research examining passive and active transport mechanisms for nonapeptides across the BBB, with DSIP as a model compound for small neuropeptide CNS delivery.
• Intranasal neuropeptide bioavailability: Studies examining the pharmacokinetic profile of DSIP following intranasal administration, including nasal mucosal absorption, plasma kinetics, and CNS distribution in rodent models.

What Are the Potential Side Effects of DSIP?

The following observations are derived exclusively from preclinical animal studies and general neuropeptide class considerations. No human clinical safety data has been established for DSIP as a research compound.

• Low acute toxicity has been generally reported in available preclinical rodent literature at doses used in neuroendocrine and sleep research contexts. Published LD50 data in commonly used laboratory rodent species is not prominently available in peer-reviewed literature.
• Neuroendocrine off-target effects are plausible given DSIP’s observed interactions with multiple pituitary hormone systems; the breadth of neuroendocrine modulation in non-target systems is not fully characterized.
• No chronic toxicity data is available for any species. Long-term safety, reproductive toxicity, genotoxicity, and organ-level toxicity remain uncharacterized.
• Data remains limited. No human safety data has been established.

Risk & Handling

Handling Precautions

DSIP Nasal Spray is intended for use by trained laboratory personnel only. The following precautions apply:

• PPE required: nitrile gloves, laboratory coat, and eye protection at minimum.
• Handle reconstituted nasal spray solution in a clean laboratory environment; avoid aerosol generation during manipulation or transfer operations.
• Pipetting and aliquoting should be performed with calibrated laboratory equipment; avoid contact with mucous membranes, eyes, or skin.
• Dispose of all biological waste in accordance with institutional biosafety protocols and applicable local regulations.

Exposure Risks

Risk Tier: LOW to MODERATE

DSIP is a naturally occurring nonapeptide with a characterized endogenous presence across multiple mammalian species. No human safety data has been established for its use as a research compound. Available preclinical data indicates low acute systemic toxicity at research-relevant concentrations. The compound’s neuroendocrine activity profile warrants standard biological research handling precautions. Chronic toxicity, reproductive toxicity, and genotoxicity have not been independently characterized.

Storage

• Lyophilized: Store at −20°C in a desiccated, airtight container protected from light and moisture. Stable for up to 24 months under these conditions.
• Reconstituted / Nasal Spray: Maintain at 2–8°C. Use within 28 days of preparation. Do not freeze reconstituted solution. Protect from direct light exposure.
• Freeze-thaw: Avoid repeated freeze-thaw cycles of the lyophilized peptide. Aliquot prior to first use to preserve peptide integrity.
• Supplied in sterile, sealed amber glass or HDPE spray container as appropriate to preserve photostability.

FAQs

Q1: What is the half-life of DSIP in preclinical plasma preparations? DSIP is a small nonapeptide subject to proteolytic degradation in biological matrices. Plasma half-life data for DSIP from preclinical rodent pharmacokinetic studies indicates relatively rapid clearance, consistent with unprotected small peptides; precise values vary across species and experimental conditions. The peptide’s endogenous presence in circulating blood at varying concentrations throughout the day has been documented in preclinical models, suggesting regulated production and clearance mechanisms. No human pharmacokinetic data has been established.

Q2: What is the recommended storage duration for the reconstituted DSIP Nasal Spray? Reconstituted DSIP nasal spray solution should be maintained at 2–8°C and used within 28 days of preparation. Lyophilized peptide stock should be stored at −20°C, desiccated and protected from light, where it is stable for up to 24 months from the manufacturing date under correct storage conditions.

Q3: Has DSIP been observed to cross the blood-brain barrier in preclinical models? Preclinical rodent studies have provided evidence suggesting DSIP can penetrate the blood-brain barrier via passive diffusion, a property relevant to intranasal delivery research. The efficiency of CNS penetration via intranasal routes is an active area of investigation in neuropeptide research and has not been fully quantified in standardized models.

Q4: What neuroendocrine interactions have been identified for DSIP in preclinical research? In preclinical preparations, DSIP has been observed to stimulate LH release, promote growth hormone-releasing factor secretion, inhibit somatostatin release, and modulate corticotropin dynamics in pituitary and hypothalamic systems. These interactions have not been attributed to a single identified receptor, and findings are not consistent across all experimental model systems examined.

Q5: Is there a known DSIP receptor? No dedicated DSIP receptor has been identified or cloned as of June 2026. The molecular target mediating DSIP’s neuroendocrine and electrophysiological effects remains uncharacterized. This represents a fundamental open question in DSIP pharmacology and is a relevant consideration for researchers designing receptor-binding or mechanistic studies.

Q6: What preclinical toxicity observations are available for DSIP? Available preclinical literature indicates low acute toxicity at doses used in neuroendocrine research contexts. No LD50 data is prominently reported in peer-reviewed literature. Chronic toxicity, reproductive toxicity, genotoxicity, and organ-level safety profiles are uncharacterized. No human safety data has been established.

Related Research Compounds

Section pending internal URL confirmation. All products listed are for laboratory and research purposes only.

References

1. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006;97(2):303–309. https://pubmed.ncbi.nlm.nih.gov/16539676/

1. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neuroscience & Biobehavioral Reviews. 1984;8(1):83–93. https://pubmed.ncbi.nlm.nih.gov/6323232/

1. Schoenenberger GA, Maier PF, Tobler HJ, Wilson K, Monnier M. The delta EEG (sleep)-inducing peptide (DSIP). Pflügers Archiv – European Journal of Physiology. 1978;376(2):119–129. https://pubmed.ncbi.nlm.nih.gov/418887/

1. Monnier M, Schoenenberger GA. Characterization, sequence, synthesis and specificity of a delta-EEG (sleep)-inducing peptide. Pflügers Archiv. 1977;374(2):119–127. https://pubmed.ncbi.nlm.nih.gov/414617/

Disclaimer

DSIP (Delta Sleep Inducing Peptide) Nasal Spray is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not evaluated the statements on our website. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co